# Jeff Clark

> Jeff Clark is a Series A investor at The Aurora Funds backing Biotechnology. See 18 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: [The Aurora Funds](https://shizune.co/investors/profile/the-aurora-funds)
- Location: Raleigh, United States
- Total investments: 18
- Last investment: Mar 2022
- Lead investor: 28%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/jeff-clark/11/989/172

Jeff Clark is a Managing Partner at Aurora Funds. He Attended Duke University - The Fuqua School of Business.

## Contacts

5 contacts available for Jeff Clark: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/jeff-clark?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 28% |
| Health Care | 4 | 22% |
| Therapeutics | 2 | 11% |
| Farming | 1 | 6% |
| Chemical | 1 | 6% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 22% |
| Series C | 4 | 22% |
| Series D | 3 | 17% |
| Seed | 2 | 11% |
| Series E | 2 | 11% |

6 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Quinsite | Quinsite offers a healthcare analytics platform that enhances decision making and improves operational efficiencies. | $2.5M | Seed | Mar 24, 2022 |  |
| Metabolon | Metabolon is a technology company, develops analytical methods and software for biomarker discovery using metabolomics. It offers a biochemical profiling platform that analyzes and identifies biochemicals in the research of pharmaceutical, biotech, agriculture, cosmetic, and consumer products. Metabolon provides a unique, real-time fingerprint ofbiological system to reveal novel discoveries and realize the promise of precision medicine.The company can deliver an instantaneous snapshot of the entire physiology of a living being at a discreet point in time, as well as identify changes in that system brought about the impact of the disease, medical intervention, diet, or the environment. This deep and comprehensive view of the metabolome provides biological insights that cannot be revealed through any other research methodology, enabling life sciences researchers and drug developers to discover answers to some of biology’s most difficult questions.Metabolon was founded in 2000 and headquartered in Durham, North Carolina. | $15M | Series E | Jan 06, 2014 |  |
| Regado Biosciences | Regado Biosciences is a biopharmaceutical company, engages in the discovery and development of aptamer-based antidote-controlled therapeutics. It provides REG1 that is used in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures, which include coronary artery bypass grafting and percutaneous coronaryintervention. It was founded in 2001 and headquartered in Durham, North Carolina. | $51M | Series E | Dec 17, 2012 |  |
| Metabolon | Metabolon is a technology company, develops analytical methods and software for biomarker discovery using metabolomics. It offers a biochemical profiling platform that analyzes and identifies biochemicals in the research of pharmaceutical, biotech, agriculture, cosmetic, and consumer products. Metabolon provides a unique, real-time fingerprint ofbiological system to reveal novel discoveries and realize the promise of precision medicine.The company can deliver an instantaneous snapshot of the entire physiology of a living being at a discreet point in time, as well as identify changes in that system brought about the impact of the disease, medical intervention, diet, or the environment. This deep and comprehensive view of the metabolome provides biological insights that cannot be revealed through any other research methodology, enabling life sciences researchers and drug developers to discover answers to some of biology’s most difficult questions.Metabolon was founded in 2000 and headquartered in Durham, North Carolina. |  | Series D | Aug 29, 2011 |  |
| Regado Biosciences | Regado Biosciences is a biopharmaceutical company, engages in the discovery and development of aptamer-based antidote-controlled therapeutics. It provides REG1 that is used in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures, which include coronary artery bypass grafting and percutaneous coronaryintervention. It was founded in 2001 and headquartered in Durham, North Carolina. | $40M | Series D | Dec 17, 2009 |  |
| Metabolon | Metabolon is a technology company, develops analytical methods and software for biomarker discovery using metabolomics. It offers a biochemical profiling platform that analyzes and identifies biochemicals in the research of pharmaceutical, biotech, agriculture, cosmetic, and consumer products. Metabolon provides a unique, real-time fingerprint ofbiological system to reveal novel discoveries and realize the promise of precision medicine.The company can deliver an instantaneous snapshot of the entire physiology of a living being at a discreet point in time, as well as identify changes in that system brought about the impact of the disease, medical intervention, diet, or the environment. This deep and comprehensive view of the metabolome provides biological insights that cannot be revealed through any other research methodology, enabling life sciences researchers and drug developers to discover answers to some of biology’s most difficult questions.Metabolon was founded in 2000 and headquartered in Durham, North Carolina. |  | Series C | Dec 07, 2009 |  |
| Metabolon | Metabolon is a technology company, develops analytical methods and software for biomarker discovery using metabolomics. It offers a biochemical profiling platform that analyzes and identifies biochemicals in the research of pharmaceutical, biotech, agriculture, cosmetic, and consumer products. Metabolon provides a unique, real-time fingerprint ofbiological system to reveal novel discoveries and realize the promise of precision medicine.The company can deliver an instantaneous snapshot of the entire physiology of a living being at a discreet point in time, as well as identify changes in that system brought about the impact of the disease, medical intervention, diet, or the environment. This deep and comprehensive view of the metabolome provides biological insights that cannot be revealed through any other research methodology, enabling life sciences researchers and drug developers to discover answers to some of biology’s most difficult questions.Metabolon was founded in 2000 and headquartered in Durham, North Carolina. | $6.2M | Series C | Oct 27, 2009 |  |
| Aldagen | ALDAGEN is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. We have four product candidates in clinical trials. Our most advanced product candidate is ALD-101. We are currently conducting a pivotal Phase 3 clinical trial of ALD-101 to evaluate its efficacy in improvingumbilical cord blood, or cord blood, transplants used to treat inherited metabolic diseases in pediatric patients. We are also conducting or supporting Phase 1 or Phase 1/2 clinical trials of three other product candidates ALD--151 to improve cord blood transplants used for the treatment of leukemia; ALD-301 to treat critical limb ischemia; and ALD-201 to treat ischemic heart failure. | $18.4M | Series D | Apr 23, 2008 |  |
| Regado Biosciences | Regado Biosciences is a biopharmaceutical company, engages in the discovery and development of aptamer-based antidote-controlled therapeutics. It provides REG1 that is used in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures, which include coronary artery bypass grafting and percutaneous coronaryintervention. It was founded in 2001 and headquartered in Durham, North Carolina. | $23M | Series C | Mar 27, 2007 |  |
| Aldagen | ALDAGEN is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. We have four product candidates in clinical trials. Our most advanced product candidate is ALD-101. We are currently conducting a pivotal Phase 3 clinical trial of ALD-101 to evaluate its efficacy in improvingumbilical cord blood, or cord blood, transplants used to treat inherited metabolic diseases in pediatric patients. We are also conducting or supporting Phase 1 or Phase 1/2 clinical trials of three other product candidates ALD--151 to improve cord blood transplants used for the treatment of leukemia; ALD-301 to treat critical limb ischemia; and ALD-201 to treat ischemic heart failure. | $14.3M | Series C | Dec 19, 2006 |  |

10 of 18 investments shown.

## Co-investors
- [Sevin Rosen Funds](https://shizune.co/investors/profile/sevin-rosen-funds) — VC Fund, 5 deals together
- [Fletcher Spaght, Inc.](https://shizune.co/investors/profile/fletcher-spaght-inc) — VC Fund, 3 deals together
- [Syngenta Ventures](https://shizune.co/investors/profile/syngenta-ventures) — VC Fund, 3 deals together
- [Alexandria Real Estate Equities](https://shizune.co/investors/profile/alexandria-real-estate-equities) — VC Fund, 2 deals together
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 2 deals together
- [Harbert Growth Partners](https://shizune.co/investors/profile/harbert-growth-partners) — VC Fund, 2 deals together

## About The Aurora Funds

VC Fund · Durham, United States

The Aurora Funds is a family of venture capital funds committed to providing resources to help early stage healthcare and information technology companies reach their full potential.

5 contacts available at The Aurora Funds.

| Name | Title | Profile |
| --- | --- | --- |
| Jeff Clark | Managing Partner | — |
| Chris Kroeger | Partner | — |
| Doug Gooding | Venture Partner | — |
| Richard Brown | Venture Partner | — |
| Scott Albert | Co-Founder & Venture Partner | https://shizune.co/investors/profile/scott-albert |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Jeff Clark invest in?

Jeff Clark invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series C stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Jeff Clark?

Public channels for Jeff Clark include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Jeff Clark last invest?

The most recent investment recorded for Jeff Clark closed in Mar 2022. Shizune tracks 18 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co